After the positive weekly performance so far, there is unlikely to be much change in the Dax DE0008469008 on Thursday.
Frankfurt Stock Outlook: Little movement ahead of ECB interest rate decision
One hour before the start of trading, the X-Dax DE000A0C4CA0 signaled a loss of 0.1 percent to 24,250 points for the German benchmark index. The Eurozone's leading index, the EuroStoxx 50 EU0009658145, is also expected to be down 0.1 percent.
The day before, the DAX continued its record run with a new high of 24,346 points, extending its annual gain to 22 percent. The risk of a correction is now high, warn experts at Landesbank Helaba.
Meanwhile, the MDax DE0008467416 climbed above 31,000 points for the first time in over three years. It is in a neck-and-neck race with the DAX in the annual results.
On Thursday, investors will be waiting to see what the European Central Bank (ECB) will do with interest rates. A further cut of 0.25 percentage points is expected. However, as always, the signals from central bank President Christine Lagarde regarding the next steps will be particularly exciting.
Meanwhile, the new German Chancellor, Friedrich Merz (CDU), will meet with US President Donald Trump at the White House in the early evening Central European Time. Topics of discussion will include the war in Ukraine, NATO issues, and the tariff dispute.
Reclassifications affected some individual stocks before trading. Airbus NL0000235190, for example, fell slightly on Tradegate compared to the Xetra close after the US bank Citigroup withdrew its buy recommendation for the aircraft manufacturer's shares. The weak US dollar was said to be reducing the upside potential.
British bank Barclays lowered its thumbs-down rating on Eon DE000ENAG999 to "Equal Weight." The utility's shares fell 1 percent on Tradegate.
Bayer DE000BAY0017, on the other hand, rose 3.2 percent at the Xetra close. Goldman Sachs upgraded the shares to "buy."
Thyssenkrupp DE0007500001 is pushing ahead with the spin-off of submarine manufacturer TKMS. A stock market listing could take place in the fall. The plans are becoming more concrete, a trader said. This should support Thyssenkrupp's share price. The shares gained 1.3 percent on Tradegate before trading.
The biotech company Formycon DE000A1EWVY8 has been granted permission to market its biosimilar for the eye drug Lucentis in Brazil. Formycon shares rose 6.5 percent on Tradegate.
ad-hoc-news
